X4 Pharmaceuticals Inc. is raring to go with marketing after the firm scored U.S. FDA approval of Xolremdi (mavorixafor) capsules for patients 12 years and older with warts, hypogammaglobulinemia, infections and myelokathexis, or WHIM syndrome, to increase the number of circulating mature neutrophils and lymphocytes. Read More
In a $2.4 billion deal, Deciphera Pharmaceuticals Inc. is merging with Ono Pharmaceutical Co. Ltd. Ono is acquiring all of Deciphera’s outstanding stock shares for $25.60 each in cash. The merger helps Osaka, Japan-based Ono strengthen its oncology portfolio and its presence in the U.S. Read More
A week after Bristol Myers Squibb Co. disclosed a significant restructuring plan to focus on long-term growth drivers, the big pharma partnered with Repertoire Immune Medicines Inc. in an early stage, multiyear collaboration to develop T-cell targeted medicines for up to three autoimmune diseases, paying $65 million up front, with a potential $1.8 billion in development, regulatory and commercial milestones, along with tiered royalties. Read More
Looking beyond the U.S. biopharma industry, Sen. Bernie Sanders (I-Vt.) is now pushing the International Federation of Pharmaceutical Manufacturers and Associations to get on board with the World Health Organization’s proposed Pandemic Accord aimed at making diagnostics, treatments and vaccines available to everyone who needs them. Read More
After concluding 2023 up 11.62%, the BioWorld Biopharmaceutical Index (BBI) extended its upward trajectory into the first quarter (Q1), posting a 6.4% increase at the close of March. BBI outperformed both the Dow Jones Industrial Average (up 5.62%) and the Nasdaq Biotechnology Index (up 1.36%) by the end of Q1. Read More
Females have a much greater risk of developing an autoimmune disease than males do. Eighty percent of autoimmune disease patients are female, and specific disorders can have an even more lopsided ratio – 90% of systemic lupus erythematosus (lupus) and almost 95% of Sjögren’s disease patients are female. Read More
Antibody-drug conjugates are the hot spot for deals in Asia, but investors questioned whether oncology is really the place to be, during the Asia Bio Partnering Forum in Singapore April 24 to 25. Read More
Boston-based South Korean biotech Genosco Inc. said on April 25 that it passed a technology review required for the special listing track on the tech-heavy Kosdaq market, as it readies an IPO on the Korea Exchange. Read More
New hires and promotions in the biopharma industry, including: Alentis, Cullinan, George Medicines, Gritstone, Renagade, Repare, Rinri, Stoke. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aligos, Arbele, Biocardia, Caliway, Can-Fite, Nkgen, Recce. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Allogene, Biosenic, Biovie, Immunoengineering, Moderna, Mosaic Immunoengineering, Oncotelic, Signalchem, Sino Biological. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amgen, Apellis, Avistone, Biogen, Bristol Myers Squibb, Gilead, Hutchmed, Johnson & Johnson, Novartis, Pfizer, Ractigen, Sobi, Takeda. Read More
